Exploring the Association of Disease Modifying Therapies for Multiple Sclerosis and BTK Inhibitors with Epilepsy (P7-9.001)
To explore the association of multiple sclerosis (MS) disease modifying therapies (DMTs) and FDA-approved Bruton tyrosine kinase inhibitors (for lymphocytic malignancies) with the occurrence of epilepsy using the FDA Adverse Event Reporting System (FAERS) database.
Authors
- Nil Saez-Calveras (ORCID: https://orcid.org/0000-0002-9153-9700)
- Olaf Stüve (ORCID: https://orcid.org/0000-0002-0469-6872)
- Wayne Moore
- Jack P. Antel (ORCID: https://orcid.org/0000-0002-5148-0636)
- Amy L. Brewster (ORCID: https://orcid.org/0000-0002-3677-410X)
- Afsaneh Shirani (ORCID: https://orcid.org/0000-0002-8866-6426)
- Moein Yaqubi (ORCID: https://orcid.org/0000-0001-7299-5930)
Institutions
- Montreal Neurological Institute and Hospital (CA)
- University of British Columbia (CA)
- Southern Methodist University (US)
- Southwestern Medical Center (US)
- Southwestern Medical Center (US)
- McGill University (CA)
- University of Nebraska Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208449
- Primary Topic
- Nuclear Receptors and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00